The rise of Viagra and its impact on the medicinal landscape presents a complicated question for shareholders. While the first sales data were remarkable, the patent has lapsed, leading to a deluge of copycat alternatives that are chipping away at profit. Moreover, the industry is facing difficulties related to aging trends and shifting healthca… Read More